S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot

Barinthus Biotherapeutics (BRNS) Competitors

$2.95
+0.12 (+4.24%)
(As of 03/1/2024 ET)

BRNS vs. VACC, CMRX, CARM, IOBT, ANVS, DMAC, GALT, GTHX, ANIX, and CRVS

Should you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Vaccitech (VACC), Chimerix (CMRX), Carisma Therapeutics (CARM), IO Biotech (IOBT), Annovis Bio (ANVS), DiaMedica Therapeutics (DMAC), Galectin Therapeutics (GALT), G1 Therapeutics (GTHX), Anixa Biosciences (ANIX), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical preparations" industry.

Barinthus Biotherapeutics vs.

Vaccitech (NASDAQ:VACC) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability, institutional ownership and community ranking.

Vaccitech is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaccitech$13.42M8.47$5.34M-$1.43-2.06
Barinthus Biotherapeutics$44.70M2.54$5.34M-$2.02-1.46

In the previous week, Barinthus Biotherapeutics had 3 more articles in the media than Vaccitech. MarketBeat recorded 4 mentions for Barinthus Biotherapeutics and 1 mentions for Vaccitech. Vaccitech's average media sentiment score of 1.19 beat Barinthus Biotherapeutics' score of 0.00 indicating that Barinthus Biotherapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vaccitech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Barinthus Biotherapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

26.1% of Vaccitech shares are owned by institutional investors. Comparatively, 26.1% of Barinthus Biotherapeutics shares are owned by institutional investors. 6.0% of Vaccitech shares are owned by insiders. Comparatively, 6.0% of Barinthus Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Vaccitech has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.49, suggesting that its share price is 149% less volatile than the S&P 500.

Vaccitech received 14 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 70.83% of users gave Vaccitech an outperform vote.

CompanyUnderperformOutperform
VaccitechOutperform Votes
17
70.83%
Underperform Votes
7
29.17%
Barinthus BiotherapeuticsOutperform Votes
3
100.00%
Underperform Votes
No Votes

Vaccitech presently has a consensus price target of $9.31, indicating a potential upside of 215.68%. Barinthus Biotherapeutics has a consensus price target of $15.00, indicating a potential upside of 408.47%. Given Vaccitech's stronger consensus rating and higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Vaccitech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaccitech
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Barinthus Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Barinthus Biotherapeutics' return on equity of -23.41% beat Vaccitech's return on equity.

Company Net Margins Return on Equity Return on Assets
Vaccitech-409.18% -23.41% -20.85%
Barinthus Biotherapeutics -409.18%-34.72%-30.65%

Summary

Barinthus Biotherapeutics beats Vaccitech on 8 of the 14 factors compared between the two stocks.


Get Barinthus Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BRNS vs. The Competition

MetricBarinthus BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$113.75M$7.30B$5.21B$7.62B
Dividend YieldN/A2.84%2.82%3.87%
P/E Ratio-1.4619.21257.1618.81
Price / Sales2.54452.263,095.74110.41
Price / Cash10.9219.1499.8655.35
Price / Book0.454.704.534.54
Net Income$5.34M$162.03M$114.95M$211.55M
7 Day Performance9.67%7.67%5.71%3.36%
1 Month Performance10.07%15.58%11.26%6.68%
1 Year PerformanceN/A9.19%13.49%8.85%

Barinthus Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VACC
Vaccitech
0 of 5 stars
$2.68
+3.1%
$9.31
+247.5%
-6.3%$103.31M$13.42M-1.8733News Coverage
CMRX
Chimerix
4.5178 of 5 stars
$1.18
-0.8%
$8.00
+578.0%
-26.4%$104.89M$1.13M-1.2389Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
CARM
Carisma Therapeutics
2.1088 of 5 stars
$2.48
+1.2%
$10.00
+303.2%
N/A$100.09M$40M-0.66N/AGap Down
IOBT
IO Biotech
2.5879 of 5 stars
$1.48
-1.3%
$8.33
+463.1%
-32.0%$97.50MN/A-0.6057Positive News
Gap Up
ANVS
Annovis Bio
1.31 of 5 stars
$10.33
+1.5%
$34.25
+231.6%
-47.8%$109.29MN/A-2.425Analyst Downgrade
DMAC
DiaMedica Therapeutics
1.4921 of 5 stars
$2.88
-0.7%
$7.00
+143.5%
+77.5%$110.07MN/A-4.6416
GALT
Galectin Therapeutics
2.3519 of 5 stars
$1.78
-4.3%
$11.00
+518.0%
-5.9%$110.09MN/A-2.3412News Coverage
GTHX
G1 Therapeutics
3.8681 of 5 stars
$2.15
-0.5%
$9.00
+318.6%
+1.6%$111.47M$77.89M-1.46170Earnings Report
Analyst Report
Short Interest ↑
Analyst Revision
News Coverage
ANIX
Anixa Biosciences
2.8703 of 5 stars
$3.56
-5.6%
$10.50
+194.9%
-28.6%$112.89M$210,000.00-11.134Short Interest ↓
CRVS
Corvus Pharmaceuticals
2.7659 of 5 stars
$2.31
+0.4%
$6.63
+186.8%
+202.7%$113.28MN/A-3.6129Short Interest ↓
Gap Up

Related Companies and Tools

This page (NASDAQ:BRNS) was last updated on 3/2/2024 by MarketBeat.com Staff